Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
7
Bullish
5
Bearish
13
Neutral
7
Bullish
26
Bearish
11
Neutral
0
Bullish
21
Discovery themes featuring this stock
Aarti Drugs Limited is an integrated Indian manufacturer of APIs, pharmaceutical intermediates, specialty chemicals and formulations, operating GMP-certified plants with an in-house formulations arm (Pinnacle Life Science) focused on regulated market dossiers and contract manufacturing.
Operationally the company reported consolidated Q3 FY26 revenue of INR602.9 crores (+8% YoY) with EBITDA of INR56.3 crores and a 9.3% EBITDA margin; PAT rose sharply to INR40.5 crores (+58% YoY) driven by improved volumes and mix despite short-term utilization and pricing headwinds.
Key strategic developments include the Sayakha methylamine plant (capturing backward integration for antidiabetic intermediates) and a salicylic acid facility now producing >300 tons per month; management expects rapid ramp-up of Sayakha to ~50% by Mar–Apr 2026 and further to 75%+ within the following quarters.
Formulations are emerging as a higher-value growth engine: Q3 formulations revenue grew 58% YoY with 67% export share, oncology dossiers and a US/EU‑approved OSD and oncology facility at Baddi position the company to monetize higher-margin regulated markets over the medium term.
Management guidance highlights normalized pricing and an inflection in realizations from January, targeted 12–15% volume growth in FY27, and disciplined capex while addressing one-time ramp-up and refurbishment impacts that compressed margins in the reported quarter.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,693 Cr
Moderate Risk
18.9
36.7
1.2
2.4
551.10
318.60
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aarti Drugs Ltd (AARTIDRUGS) is currently trading at 405.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aarti Drugs Limited is an integrated Indian manufacturer of APIs, pharmaceutical intermediates, specialty chemicals and formulations, operating GMP-certified plants with an in-house formulations arm (Pinnacle Life Science) focused on regulated market dossiers and contract manufacturing. Operationally the company reported consolidated Q3 FY26 revenue of INR602.9 crores (+8% YoY) with EBITDA of INR56.3 crores and a 9.3% EBITDA margin; PAT rose sharply to INR40.5 crores (+58% YoY) driven by improved volumes and mix despite short-term utilization and pricing headwinds. Key strategic developments include the Sayakha methylamine plant (capturing backward integration for antidiabetic intermediates) and a salicylic acid facility now producing >300 tons per month; management expects rapid ramp-up of Sayakha to ~50% by Mar–Apr 2026 and further to 75%+ within the following quarters. Formulations are emerging as a higher-value growth engine: Q3 formulations revenue grew 58% YoY with 67% export share, oncology dossiers and a US/EU‑approved OSD and oncology facility at Baddi position the company to monetize higher-margin regulated markets over the medium term. Management guidance highlights normalized pricing and an inflection in realizations from January, targeted 12–15% volume growth in FY27, and disciplined capex while addressing one-time ramp-up and refurbishment impacts that compressed margins in the reported quarter.
Over the past 52 weeks, Aarti Drugs Ltd has traded between a low of ₹318.60 and a high of ₹551.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aarti Drugs Ltd has a market capitalization of approximately 3,693.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aarti Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,693.24 Cr, Aarti Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aarti Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aarti Drugs Ltd is 18.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Q4 FY26 consolidated revenue was INR 721.1 crore, up 6% year-on-year and 20% quarter-on-quarter.
FY26 revenue rose 7% year-on-year to ₹2,567.7 crore, EBITDA increased 3% to ₹311.6 crore, and PAT rose 16% to ₹194.9 crore.
Management reported Q4 FY25 revenue of ₹679 crore with PAT of ₹63 crore, up 33% year-on-year, and a PAT margin of 9.2%.
The case involved a Show Cause Notice from the CGST authority for a potential demand of ₹230.70 crores related to IGST refunds for the financial years 2017-18 to 2021-22.
Board Meeting
Aarti Drugs Ltd informed exchanges that its Board will meet on 2026-07-31 to consider and approve audited financial results for the quarter ended June 30, 2026. Trading window closed until 48 hours after declaration.
Board Meeting
Aarti Drugs Ltd will hold a Board meeting on 2026-07-31 to consider and approve audited financial results for the quarter ended 2026-06-30; trading window closed until 48 hours after declaration.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1258.40 | 4,358 Cr | — | 6.28 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
360.50 | 3,928 Cr | 84.23 | 13.65 | 0.19 | 16.22 | 14.47 | 9.27 | ||
539.90 | 3,797 Cr | 46.37 | 1.40 | 0.00 | 2.88 | 3.79 | 6.77 | ||
377.85 | 3,793 Cr | 59.10 | 5.70 | 0.03 | 9.66 | 11.45 | 4.78 | ||
405.05 | 3,693 Cr | 18.94 | 2.38 | 0.49 | 12.58 | 11.51 | 6.92 | ||
386.60 | 3,566 Cr | 34.97 | 4.54 | 0.11 | 12.98 | 12.14 | 6.46 | ||
| Median: 7 Co. | — | 405.05 | 3,797 Cr | 43.98 | 4.97 | 0.08 | 11.39 | 11.51 | 6.77 |
